Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections | Zendy

Dan Li | Zendy; Philip E. Sabato | Zendy; Benjamin Guiastrennec | Zendy; Aziz Ouerdani | Zendy; Hwa-ping Feng | Zendy; Vincent Duval | Zendy; Carisa S De Anda | Zendy; P.S. Sears | Zendy; Margaret Z. Chou | Zendy; C. Hardalo | Zendy; Natalya Broyde | Zendy; Matthew L. Rizk | Zendy

Open Access

Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections

Author(s) -

Dan Li,

Philip E. Sabato,

Benjamin Guiastrennec,

Aziz Ouerdani,

Hwa-ping Feng,

Vincent Duval,

Carisa S De Anda,

P.S. Sears,

Margaret Z. Chou,

C. Hardalo,

Natalya Broyde,

Matthew L. Rizk

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00895-21

Subject(s) - medicine , pharmacokinetics , pharmacodynamics , population , skin infection , pharmacology , staphylococcus aureus , environmental health , biology , bacteria , genetics

Tedizolid phosphate is an oxazolidinone antibacterial agent approved for the treatment of Gram-positive acute bacterial skin and skin structure infections (ABSSSIs) in patients aged ≥12 years. To support the use of tedizolid phosphate in adolescents with ABSSSIs, a population pharmacokinetic (PK) model, developed using adult and pediatric data, was updated to include PK data from a phase 3 clinical trial (PN012) that evaluated the safety and efficacy of once-daily oral or intravenous 200-mg tedizolid phosphate treatment in adolescents (12 to <18 years) with ABSSSIs, along with emerging data from a phase 1 trial (PN013) in children (2 to <12 years).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research